Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Bay 59-3074 是选择性的CB1/CB2受体的部分激动剂,其在 CB1 受体 (Ki:48.3 nM) 和 CB2 受体 (Ki:45.5 nM)。它可用于缓解疼痛的研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 233 | 现货 | ||
5 mg | ¥ 398 | 现货 | ||
10 mg | ¥ 663 | 现货 | ||
25 mg | ¥ 1,230 | 现货 | ||
50 mg | ¥ 1,980 | 现货 | ||
100 mg | ¥ 3,730 | 现货 | ||
200 mg | ¥ 5,330 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 455 | 现货 |
产品描述 | Bay 59-3074 is a CB1/CB2 receptor partial agonist (Ki: 48.3/45.5 nM). In rat models of chronic neuropathic and inflammatory pain, it displays anti-hyperalgesic and antiallodynic properties. |
靶点活性 | CB1:48.3nM(ki), CB2:45.5 nM(ki) |
体外活性 | analgesic, antihyperalgesic, and antiallodynic properties in rat models of acute and chronic pain. The reference concentration is 10 μM. |
体内活性 | In rat models of chronic neuropathic (chronic constriction injury, spared nerve injury, tibial nerve injury, and spinal nerve ligation models) and inflammatory pain (carrageenan and complete Freund's adjuvant models), BAY 59-3074 (0.3-3 mg/kg, p.o.) induced antihyperalgesic and antiallodynic effects against thermal or mechanical stimuli. Antiallodynic efficacy of BAY 59-3074 (1 mg/kg, p.o.) in the spared nerve injury model was maintained after 2 weeks of daily administration. However, tolerance developed rapidly (within 5 days) for cannabinoid-related side effects, which occur at doses above 1 mg/kg (e.g., hypothermia). Uptitration from 1 to 32 mg/kg p.o. (doubling of daily dose every 4th day) prevented the occurrence of such side effects, whereas antihyperalgesic and antiallodynic efficacy was maintained/increased. No withdrawal symptoms were seen after abrupt withdrawal following 14 daily applications of 1 to 10 mg/kg p.o. |
分子量 | 453.36 |
分子式 | C18H13F6NO4S |
CAS No. | 406205-74-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (110.29 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.2058 mL | 11.0288 mL | 22.0575 mL | 55.1438 mL |
5 mM | 0.4412 mL | 2.2058 mL | 4.4115 mL | 11.0288 mL | |
10 mM | 0.2206 mL | 1.1029 mL | 2.2058 mL | 5.5144 mL | |
20 mM | 0.1103 mL | 0.5514 mL | 1.1029 mL | 2.7572 mL | |
50 mM | 0.0441 mL | 0.2206 mL | 0.4412 mL | 1.1029 mL | |
100 mM | 0.0221 mL | 0.1103 mL | 0.2206 mL | 0.5514 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Bay 59-3074 406205-74-1 GPCR/G Protein Cannabinoid Receptor inhibit Inhibitor Bay 593074 Bay 59 3074 inhibitor